The stock of Aurinia Pharmaceuticals Ord (NASDAQ:AUPH) registered a decrease of 2.84% in short interest. AUPH’s total short interest was 10.86M shares in January as published by FINRA. Its down 2.84% from 11.18 million shares, reported previously. With 662,300 shares average volume, it will take short sellers 16 days to cover their AUPH’s short positions. The short interest to Aurinia Pharmaceuticals Ord’s float is 29.88%.
The stock increased 3.68% or $0.1934 during the last trading session, reaching $5.4534. About 629,016 shares traded. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has risen 200.00% since January 12, 2017 and is uptrending. It has outperformed by 183.30% the S&P500.
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company has market cap of $451.21 million. The firm is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It currently has negative earnings. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Coverage
Among 5 analysts covering Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aurinia Pharmaceuticals Inc had 11 analyst reports since June 30, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 23 by Cantor Fitzgerald. The firm has “Outperform” rating given on Monday, October 23 by Leerink Swann. The firm has “Buy” rating by H.C. Wainwright given on Friday, December 30. Cantor Fitzgerald initiated it with “Overweight” rating and $14.0 target in Tuesday, April 11 report. The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) earned “Speculative Buy” rating by Canaccord Genuity on Wednesday, September 13. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, October 24. Cantor Fitzgerald maintained Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) on Friday, August 11 with “Buy” rating. The rating was initiated by H.C. Wainwright on Thursday, June 30 with “Buy”. As per Monday, June 5, the company rating was maintained by Cantor Fitzgerald.
More important recent Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) news were published by: Businesswire.com which released: “Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace …” on January 04, 2018, also Fool.com published article titled: “3 Stocks Wall Street Hasn’t Heard of Yet”, Fool.com published: “Is Aurinia Pharmaceuticals a Buy?” on December 19, 2017. More interesting news about Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) was released by: Prnewswire.com and their article: “Pre-Market Technical Scan on Biotech Equities — Aurinia Pharma, Alder …” with publication date: January 02, 2018.